• WuXi Biologics added to the FTSE4Good Index Series for a sixth straight year.
• Inclusion cited strong ESG performance, ranking in the top 4% of the global health care sector.
• Recognition highlighted governance, ethics, labor standards, environmental management, sustainability strategy, tied to its Green CRDMO model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607282227PR_NEWS_USPR_____CN14595) on July 29, 2026, and is solely responsible for the information contained therein.